Side Effects of Butalbital
Butalbital causes drowsiness, light-headedness, dizziness, sedation, shortness of breath, nausea, vomiting, and abdominal pain as its most common adverse effects, with serious risks including habit formation, withdrawal seizures, intoxication indistinguishable from alcohol, medication-overuse headache, and potentially fatal respiratory depression when combined with other CNS depressants. 1
Common Side Effects
The most frequently reported adverse reactions include 1:
- Drowsiness and sedation
- Light-headedness and dizziness
- Shortness of breath
- Nausea, vomiting, and abdominal pain
- Intoxicated feeling
These CNS depressant effects can significantly impair function—butalbital produces intoxication clinically indistinguishable from alcohol intoxication, with documented driving impairment including horizontal and vertical nystagmus, lack of convergence, poor motor coordination, balance problems, and speech difficulties 2.
Serious and Life-Threatening Risks
Addiction and Dependence
Butalbital is habit-forming and leads to tolerance, dependence, and addiction 3, 4. The barbiturate works via GABA receptors and can build up in the system, causing intractable seizures 3.
Withdrawal Syndrome
Abrupt discontinuation after long-term use causes withdrawal seizures, which have been documented even in newborns whose mothers used butalbital during pregnancy 1. If discontinuation is necessary, the medication should be weaned slowly over 2 weeks to avoid acute withdrawal 3.
Respiratory and Cardiovascular Depression
Butalbital has central nervous system and respiratory depressive effects 3. When combined with anesthetics or other CNS depressants (alcohol, opioids, benzodiazepines), it may cause hypotension, profound sedation, and death 3, 1.
Medication-Overuse Headache
Despite being used to treat headaches, butalbital-containing products frequently cause drug-induced headache (medication-overuse headache) and rebound headache upon withdrawal 5, 4. This creates a vicious cycle of increasing headache frequency, often resulting in daily headaches 5.
Less Common but Important Side Effects
Infrequently observed effects include 1:
- CNS effects: headache, shaky feeling, tingling, agitation, fainting, fatigue, numbness, sluggishness, seizures, mental confusion, excitement, or depression (particularly in elderly or debilitated patients)
- Cardiovascular: tachycardia
- Dermatological: pruritus, and rare but serious reactions including toxic epidermal necrolysis and erythema multiforme
- Hematologic: thrombocytopenia, agranulocytosis (from acetaminophen component)
- Other: dry mouth, hyperhidrosis, difficulty swallowing, constipation, diuresis
Drug Interactions
Butalbital has multiple drug-drug interactions 3:
- MAO inhibitors enhance CNS effects 1
- Additive CNS depression with opioids, alcohol, general anesthetics, tranquilizers, and sedative-hypnotics 1
- Induces hepatic CYP450 enzymes, increasing metabolic clearance of other medications and exhibiting auto-induction leading to tolerance 6
Special Populations
Pregnancy and Lactation
Animal reproduction studies have not been conducted, but withdrawal seizures have been reported in newborns exposed in utero 1. Recent evidence suggests associations with certain congenital heart defects (tetralogy of Fallot, pulmonary valve stenosis, secundum-type atrial septal defect) 7. Butalbital is excreted in breast milk 1.
Elderly Patients
Butalbital is substantially excreted by the kidney, and elderly patients with decreased renal function face greater risk of toxic reactions 1. Mental confusion, excitement, or depression occur more frequently in elderly or debilitated patients 1.
Critical Clinical Pitfalls
The 2025 American College of Physicians guidelines explicitly recommend against using butalbital for acute episodic migraine 8. The 2002 U.S. Headache Consortium guidelines specifically discourage butalbital-containing products for migraine, as they lead to poor migraine control, disability, drug-induced headaches, and withdrawal symptoms 5. No controlled trials demonstrate benefit over placebo for migraine treatment 9.
The perioperative consensus is clear: butalbital should ideally be held on the day of operation, but if used long-term, it must be continued perioperatively to avoid potentially fatal acute withdrawal if weaning over 2 weeks was not possible 3.